Skip to content

Neuroplasticity: all studies

Page 41 of 178: studies 401 to 410 of 1,772, newest first. Back to the neuroplasticity overview

Research

Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms.

Cellular and Molecular Life Sciences February 27, 2024 Radhika Rawat, Elif Tunc-Ozcan, Sara Dunlop et al. 17 citations

Administration of multiple subanesthetic doses of ketamine increases the duration of antidepressant effects relative to a single ketamine dose, but the mechanisms mediating this sustained effect are unclear. Here, we demonstrate that ketamine's rapid and sustained effects on affective behavior are mediated by separate and temporally distinct mechanisms. The rapid effects of a single dose of...

The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness

Psychoactives February 26, 2024 Frankie A. Colosimo, Philip Borsellino, Reese I. Krider et al. 8 citations

The human brain is an extraordinarily complex organ responsible for all aspects of cognition and control. Billions of neurons form connections with thousands of other neurons, resulting in trillions of synapses that create a vast and intricate network. This network is subjected to continuous remodeling that adapts to environmental and developmental changes. The resulting neuroplasticity is...

Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.

BMC Neuroscience February 5, 2024 Robin J Murphy, Kate Godfrey, Alexander D Shaw et al. 16 citations

Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have demonstrated enhancing effects on neuroplasticity, which cannot be measured directly in humans, but may be indexed by non-invasive electroencephalography (EEG) paradigms. This study used a visual long-term potentiation (LTP) EEG paradigm to test the...

Unique Effects of (R)-Ketamine Compared to (S)-Ketamine on EEG Theta Power in Rats.

Pharmaceuticals February 1, 2024 Dóra Pothorszki, Szabolcs Koncz, Dóra Török et al. 7 citations

Differences in the pharmacological effects of (S)-ketamine and (R)-ketamine are at the focus of research. Clinical data and our rat studies confirmed the antidepressant effect of (S)- but not (R)-ketamine, with similar differences in quantitative electroencephalogram (EEG) and sleep effects. In contrast, studies mainly on mice showed some stronger, preferable effects of (R)-ketamine. EEG theta...

Do the therapeutic effects of psilocybin involve actions in the gut?

TIPS - Trends in Pharmacological Sciences February 1, 2024 Felicia Reed, Claire J. Foldi 22 citations

The psychedelic compound psilocybin has recently emerged as a therapeutic intervention for various mental health conditions. Psilocybin is a potent agonist of serotonin (5-HT) receptors (5-HTRs), which are expressed in the brain and throughout peripheral tissues, with particularly high expression in the gastrointestinal (GI) tract. However, no studies have investigated the possibility that...

A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets.

Translational Psychiatry January 19, 2024 Judit Biosca-Brull, Genís Ona, Lineth Alarcón-franco et al. 5 citations

Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the mechanisms that may underlie its anti-addictive effects are still not defined. This study aims to identify changes in gene expression induced by a single oral dose of IBO in the cortex of mice by means of a transcriptomic analysis for the first time. Our results showed significant alterations in gene...

Rapid-acting antidepressant drugs modulate affective bias in rats

Science Translational Medicine January 10, 2024 Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al. 26 citations

How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....

If psychedelics heal, how do they do it?

Proceedings of the National Academy of Sciences January 3, 2024 Carolyn Beans

Understanding the biological basis of social anxiety disorder (SAD), one of the most disabling of the anxiety disorders, will allow for novel treatment strategies to be developed. Here, we show that gut microbiota may be such a target. Mice ...Social anxiety disorder (SAD) is a crippling psychiatric disorder characterized by intense fear or anxiety in social situations and their avoidance....

Imagination, ecologized and enacted: driven by the historicity of affordance competition.

Frontiers in Psychology 2024 Caroline Stankozi 2 citations

Together, ecological psychology and enactivism can explain imagination as being driven by affordance competition. This paper presents synaptic plasticity as a hotspot for the respective historicity. First, (i) affordances are introduced as directly perceptible on the ecological view, and as co-created by an individual on the enactive view. After pointing out their compatibility, (ii) empirical...

Mechanisms of SSRI Therapy and Discontinuation.

Current Topics in Behavioral Neurosciences 2024 Trevor Sharp, Helen M Collins 40 citations

SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health problems in today's society. Despite this, SSRIs suffer from a slow onset of therapeutic effect and relatively poor efficacy as well as adverse effects, with recent concerns being focused on a disabling SSRI discontinuation syndrome. The mechanism...